A Radiobrominated Tyrosine Kinase Inhibitor for EGFR with L858R/T790M Mutations in Lung Carcinoma

A Radiobrominated Tyrosine Kinase Inhibitor for EGFR with L858R/T790M Mutations in Lung Carcinoma

Activating double mutations L858R/T790M in the epidermal growth factor receptor (EGFR) region are often observed as the cause of resistance to tyrosine kinase inhibitors (TKIs). Third-generation EGFR-TKIs, such as osimertinib and rociletinib (CO-1686), was developed to target such resistance mutatio...

Full description

Bibliographic Details
Main Authors: Muammar Fawwaz, Kenji Mishiro, Ryuichi Nishii, Akira Makino, Yasushi Kiyono, Kazuhiro Shiba, Seigo Kinuya, Kazuma Ogawa
Format: Article
Language:English
Published: MDPI AG 2021-03-01
Series:Pharmaceuticals
Subjects:
tyrosine kinase inhibitors
L858R/T790M
imaging probes
bromine-labeled
PET
Online Access:https://www.mdpi.com/1424-8247/14/3/256

Internet

https://www.mdpi.com/1424-8247/14/3/256

Similar Items